Published in Biotech Law Weekly, February 23rd, 2007
As part of the agreement, Heska Corp. has exclusively licensed veterinary rights to the portfolio.
"This agreement provides us with additional capital as well as exclusive veterinary rights to the technology underlying this patent portfolio," said Robert Grieve, Heska's chairman and CEO. "We intend to continue to focus our resources on the companion animal health market."
"We are committed to being a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.